Shots:
- The Takeda‘s P-III (FirstLight & RadiantLight) trial assessed oveporexton (BID) in NT1 pts over 12wks, where FirstLight randomized 168 pts to 3 arms (2mg, 1mg & PBO), while RadiantLight randomized 105 pts to two arms (2mg & PBO); regulatory filing is under review in the US (priority review), China & Japan
- At Wk. 12, oveporexton improved daily functioning across all 6 FINI domains & enhanced cognition, with objective & patient-reported measures showing benefits in attention, executive function, & memory; ~70% pts reported no significant cognitive difficulties vs ~15%
- Oveporexton also improved sleep quality, reduced hallucinations & sleep paralysis, decreased disturbed nighttime sleep at the 2/2mg dose, & shifted REM sleep patterns toward those seen in healthy individuals. additional analyses to be presented on microsleeps & overall NT1 symptom burden
Ref: Businesswire | Image: Takeda | Press Release
Related News: Takeda Reports P-III (LATITUDE Atlas) Trial Data on Zasocitinib for Plaque Psoriasis (PsO)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
